Diabetes pill could slash heart attack risk in millions

NCT ID NCT05441267

Ongoing Disease control Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a daily semaglutide tablet can safely reduce the risk of heart attacks, strokes, and related deaths in over 21,000 adults with type 2 diabetes who have never had a heart attack or stroke. Participants take either semaglutide or a placebo pill for several years. The goal is to see if this medication, already used for diabetes, can also protect the heart.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide oral tablet
What this could lead to: If successful, this could provide a simple daily pill to lower the risk of heart attacks and strokes in people with type 2 diabetes.
What could go wrong: This is a large, late-stage trial, but results are not yet available. Semaglutide can cause side effects like nausea or vomiting, and it may not prove effective for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Clinical Trial Service Unit and Epidemiological Studies Unit

Oxford, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.